Lindahl advises Senzime AB on a directed new share issue of SEK 100 million
Lindahl has advised Senzime AB (publ) in connection with a directed new share issue that will provide the company with SEK 100 million before transaction costs.
The subscription price was determined through an accelerated bookbuilding process, with Carnegie Investment Bank acting as financial adviser.
About Senzime
Senzime AB is a company listed on Nasdaq Stockholm that develops and markets CE and FDA approved monitoring systems for patients undergoing anaesthesia.
Lindahl's team consisted of Mattias Prage, Andreas Mellberg and Michaela Larsson.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatMichaela Larsson
Associate | AdvokatCarousel items
-
News articles
10/9/2026
The Climate Transition: What It Means for Your Business
Lindahl and the Oxford Climate Policy Monitor hosted a seminar in Malmö exploring climate policy, business opportunities, regulatory risks and the transition ahead.
-
Knowledge
10/9/2026
New ruling from the Swedish Competition Authority: Instructed ÄTA works deemed an unlawful direct award
Sweden's Competition Authority has ruled that instructed ÄTA works ordered under a construction contract amounted to an unlawful direct award, applying its 2024 legal analysis on ÄTA rules and public procurement law.
-
Cases and transactions
10/2/2026
Lindahl advises NordAmps AB (publ) on listing on Nasdaq First North Growth Market
Lindahl has acted as legal counsel to NordAmps AB (publ) in connection with the company’s listing on Nasdaq First North Growth Market.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Read more news and insights?
